Fiscal Year 2011 Annual Review of Byetta® (Exenatide)/Victoza® (Liraglutide)

Oklahoma Health Care Authority
April 2012

Current Prior Authorization of Byetta/Victoza

There is a step therapy edit in the system to detect metformin, sulfonylurea, or thiazolidinedione usage for at least 30 days within the previous 120 days. Members without one of these medications in the system would be eligible to petition.

Prior Authorization Criteria:

1. Patients must have Type 2 diabetes and currently taking metformin, sulfonylurea, thiazolidinediones, or a combination, for at least 90 days within the last 180 days, and have not achieved adequate glycemic control.
2. Clinical exception may be allowed if prescribed by an endocrinologist.
3. Quantity limit of 3 cartridiges per 30 days applies (3.6 mls & 7.2mls) for Byetta® applies.
4. Quantity Limit of 3 penpaks (9mls) per 30 days for Victoza® applies

Utilization of Byetta®/Victoza®

Comparison of Fiscal Year Utilization

Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2010	214	824	$237,590.54	$288.34	$8.30	2,226	28,623
2011	312	1,170	$395,836.32	$338.32	$10.01	5,732	39,543
% Change	45.80%	42.00%	66.60%	17.30%	20.60%	157.50%	38.20%
Change	98	346	$158,245.78	$49.98	$1.71	3,506	10,920

Demographics of Members Utilizing Byetta®/Victoza®: FY 2011



Top Prescribers of Byetta®/Victoza® by Claims: FY 2011



Utilization Details: FY 2011

Medication	Claims	Units	Days	Members	Paid	Units/ Day	Claims/ Member	Per-diem
BYETTA 10MCG INJ	549	1,549	19,414	130	$177,052.71	0.08	4.22	$9.12
BYETTA 5MCG INJ	168	211	5,308	67	$43,677.63	0.04	2.51	$8.23
VICTOZA 6MG/ML INJ	453	3,972	14,821	138	$175,105.98	0.27	3.28	$11.81
Totals	**1,170**	**5,732**	**39,543**	***231**	**$395,836.32**	**0.14**	**3.75**	**$10.01**

***Total Number of Unduplicated Members**

Prior Authorization of Byetta®/Victoza® Products

There were a total of 170 petitions submitted for this category during fiscal year 2011. The following shows the status of the submitted petitions.



Market News and Updates

- January 2012 – Bydureon®, a once weekly formulation of exenatide made by Amylin Pharmaceuticals was approved by the FDA and was made available on the market shortly there-after.
- January 2012 – all GLP-1 receptor agonists (Byetta®, Victoza®, and Bydureon®) became part of the Diabetes Medication Product Based Prior Authorization Category. The criteria for that category applies.

Conclusion and Recommendations

The College of Pharmacy recommends no changes to this category at this time.